In this study (published by Pecenka, C.; Debellut, F.; Bar-Zeev N., Anwari P., Nonvignon J., Shamsuzzaman M., and Clark A., in  Vaccine. 2018 Nov 26), the authors reevaluated the costs and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi and compared Rotarix®, ROTAVAC®, and ROTASIIL® in each country. They varied the expected price (with and without Gavi subsidy), wastage, and incremental health system costs associated with each vaccine, and assumed the same efficacy and waning assumptions following administration of two or three doses for the respective product. They concluded that countries may wish to consider new rotavirus vaccines entering the market and that countries should carefully examine multiple product attributes including price and the incremental health system costs associated with each vaccine. These costs will vary by country and may be a defining factor in determining the least costly and most cost-effective product for the populati